Medication info

Samsung Sitagliptin Plus Tablets 50/500 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate Hydrate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Samsung Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
28 tablets/bottle, 30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201603428 · Approved 2016.06.14

This product's status changed to Approval withdrawn on 2023.08.11. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, 'Patients who must not use this medicine' under Precautions for Use). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial metformin dose should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, 'General Precautions' under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, 'Patients who must not use this medicine' under Precautions for Use).

Ingredients

Manufacturer
Samsung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty controlling blood sugar
View approved original text

This medication is used in conjunction with dietary and exercise therapy to help patients control their blood sugar levels. It can be prescribed alone for patients who have not previously received antidiabetic drug therapy, and is also used as an alternative therapy in cases where blood sugar control is difficult with metformin or sitagliptin as monotherapy. Additionally, when the combined treatment of metformin with sulfonylurea, or metformin with thiazolidinedione, or insulin with metformin is insufficient, this drug can be combined to enhance blood sugar control. Its flexible use tailored to various situations effectively helps improve blood sugar control for patients.

Dosage and Administration

Adult dosage

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, 'Patients who must not use this medicine' under Precautions for Use). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial metformin dose should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, 'General Precautions' under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, 'Patients who must not use this medicine' under Precautions for Use).

Precautions

This medication is used for the treatment of diabetes and helps especially in controlling blood sugar levels. While taking this medication, serious allergic reactions may occur, although it is rare, so if symptoms such as rashes, hives, or difficulty breathing occur, it should be stopped immediately and a doctor consulted. Acute pancreatitis can occur, so if abdominal pain, vomiting, or severe abdominal pain appears, it should be reported to medical professionals immediately. This medication should not be used in patients with decreased kidney function, heart failure, acute myocardial infarction, or serious infections that can affect the kidneys. This medication must be discontinued prior to and after diagnostic tests involving radiopaque iodine agents and should only be resumed when kidney function is confirmed to be normal afterward. It is safe not to administer to women during pregnancy or those who may become pregnant, as well as nursing mothers. During the course of treatment, patients should be vigilant for hypoglycemia, as the risk may increase when used in conjunction with other hypoglycemic agents like insulin or sulfonylureas. Elderly patients may have decreased kidney function, so regular kidney function tests and possible dose adjustments are necessary. Additionally, patients with liver dysfunction or severe infections and dehydration should be cautious. Alcohol consumption should be avoided during treatment, and if sudden vomiting, diarrhea, or signs of dehydration occur, discontinuation and consultation with healthcare professionals are advised. Patients undergoing surgery should temporarily stop this medication 48 hours prior to the surgery and only resume it after oral intake is normalized and kidney function is recovered post-surgery. This medication can lower vitamin B12 levels, so regular blood tests to monitor this are recommended. In case of overdose, inform medical personnel immediately, and treatment such as hemodialysis may be required if necessary. Common side effects during treatment can include diarrhea, nausea, vomiting, headache, and upper respiratory infections. If severe joint pain or a skin rash occurs, consult a doctor immediately. Finally, it is important to consistently perform regular blood sugar tests and kidney function tests while taking this medication, and to carefully observe the therapeutic effects and side effects.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 23 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • blistering pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • decreased appetite
  • gastrointestinal disturbances
  • itching
  • dizziness
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air from entering, and it is recommended to keep it at room temperature between 1 degree and 30 degrees Celsius. This way of storage helps to maintain the effectiveness of the medication and prevent deterioration.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

28 tablets/bottle, 30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.